| | | | PERSPECTIVE | The serotonin and dopamine neurotransmitter molecules found in the urine are not serotonin and dopamine neurotransmitter molecules filtered from the renal arterial blood at the glomerulous and excreted into the urine. They are serotonin and dopamine neurotransmitter molecules synthesized by the kidneys then excreted into the urine. There is no correlation between urinary monoamine neurotransmitter levels (serotonin, dopamine, norepinephrine, and epinephrine), peripheral serotonin and dopamine neurotransmitter levels or central nervous system serotonin and dopamine neurotransmitter levels. Serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. is not able to diagnose disease such as depression, ADHD, etc. associated with serotonin and dopamine neurotransmitter levels that are not high enough, nor does it have the ability to determine the dosing of 5-HTP, tyrosine, or dopa in a starting dose, although attempts at such have been made to use serotonin and dopamine urinary neurotransmitter testing to diagnose serotonin and dopamine related neurotransmitter disease such as depression, ADHD, etc. and or determine the starting dose of 5-HTP, tyrosine, levodopa, and cysteine in addressing serotonin and dopamine neurotransmitter levels where no success has been documented. When 5-HTP is administered there is no correlation between the serotonin urinary neurotransmitter testing levels in treatment of depression, ADHD, etc. and 5-HTP dosing in treatment of disease such as depression, ADHD, etc. With all of this in mind, our research has found a correlation between urinary serotonin and dopamine neurotransmitter levels and the resolution of disease symptoms in treatment of disease such as depression, ADHD, etc. As well as a correlation between 5-HTP, tyrosine, levodopa, and cysteine dosing and urinary neurotransmitter testing levels but this only occurs when two tests are obtain on varied 5-HTP and dopa dosing and the results of the two tests are compared to reveal the urinary neurotransmitter testing phase of the serotonin and dopamine in treatment of depression, ADHD, etc. This correlation is discussed below. | | | | The 1-2-3 Serotonin and Dopamine Neurotransmitter Lab Approach | The following provides a quick overview on how to start people on the neurotransmitter precursors 5-HTP, tyrosine, levodopa, and cysteine using the clinical therapeutic approaches developed by NeuroResearch. Our research, which began in 1995 with data basing and refining serotonin and dopamine urinary neurotransmitter testing treatment in treatment of depression, ADHD, etc. in clinic with our people. This approach is currently being used by over 900 clinics in the United States and Canada. In people with serotonin and dopamine neurotransmitter dysfunction disease such as depression, ADHD, etc. involving neurotransmitter levels of serotonin, dopamine, norepinephrine, and epinephrine, the starting point of treatment is the same for each disease, use 5-HTP, tyrosine, levodopa, and cysteine. |  |  |  | At the first visit start the patient on "level 1" 5-HTP, tyrosine, levodopa, and cysteine. The patient should return to the in clinic in one week. |
| If symptoms are under control after one week, continue the “level 1” 5-HTP, tyrosine, levodopa, and cysteine dosing. If symptoms are not under control after one week, move the patient to the “level 2” 5-HTP, tyrosine, levodopa, and cysteine dosing and the patient should return to the clinic in one week. |
| If symptoms are under control after the patient has been taking “level 2” 5-HTP, tyrosine, levodopa, and cysteine dosing for one week, continue the “level 2” dosing. If after one week on "level 2" dosing symptoms are not under control increase the patient to the “level 3” 5-HTP, tyrosine, levodopa, and cysteine dosing. The patient should return to the clinic in one week. If symptoms are under control after the patient is on the “level 3” dosing for one week, continue the “level 3” dosing. If symptoms are not under control after one week of "level 3" dosing, obtain a serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. then follow the recommendations when the lab returns. People should return one week after the serotonin and dopamine urinary neurotransmitter test is obtained to review results and dosing recommendation changes. |
|
|
| | | If the goal of treatment is to optimize relief of disease symptoms, serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. prior to starting 5-HTP, tyrosine, levodopa, and cysteine is of no value. You need to treat the patient, not the lab and serotonin and dopamine baseline urinary neurotransmitter testing in treatment of depression, ADHD, etc. prior to treatment has no correlation with serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. once the patient is taking amino acids, none. Continue adjusting the 5-HTP, tyrosine, levodopa, and cysteine as guided by serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. until the patient experiences relief of symptoms or the serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. is in the phase 3 therapeutic range. Lab changes are not as important as getting disease symptoms under control, treat the patient not the lab. Once the patient's symptoms are under control, no further serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. is required. Once again, there is no correlation between serotonin and dopamine urinary neurotransmitter testing levels in treatment of depression, ADHD, etc. prior to starting 5-HTP, tyrosine, levodopa, and cysteine and serotonin and dopamine urinary neurotransmitter testing levels in treatment of depression, ADHD, etc. when people are taking serotonin and dopamine amino acid precursors 5-HTP, tyrosine, levodopa, and cysteine. | | | Urinary Serotonin and Dopamine neurotransmitter testing: The Three Phase Response | Serotonin and dopamine urinary neurotransmitter testing samples in treatment of depression, ADHD, etc. need to be collected 4 to 5 hours before bedtime just prior to the PM dose of 5-HTP, tyrosine, levodopa, and cysteine. For most people, this will be at 4 or 5 PM. In people diagnosed with one or more neurotransmitter dysfunction diseases who are not taking 5-HTP, tyrosine. or levodopa, 87% of serotonin and dopamine urinary neurotransmitter testing samples in treatment of depression, ADHD, etc. collected 4 to 5 hours before bedtime and 61% of serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. samples collected in the morning have urinary serotonin levels above the reference range of the lab. In some people, collecting serotonin and dopamine urinary neurotransmitter testing samples in treatment of depression, ADHD, etc. in the morning can lead to missing the neurotransmitter phase response on serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. While serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. may be ordered at any point after the patient has been taking the 5-HTP, tyrosine, levodopa, and cysteine for more than one week, in most people the optimal time to order serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. is after the patient has been taking the "level 3" amino acid dosing for one week with no relief of symptoms | After reviewing thousands of serotonin and dopamine urinary neurotransmitter testing assays in treatment of depression, ADHD, etc., we have observed that urinary serotonin and dopamine neurotransmitter responses to 5-HTP, tyrosine, levodopa, and cysteine (to the right) represent the response of serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. when a dosing change in a serotonin precursor (5-HTP) is given in combination with a dopamine precursor (tyrosine and/or dopa). As you examine the illustration to the right, you can see that as you increase the amino acid 5-HTP, tyrosine, levodopa, and cysteine dosing when serotonin and dopamine urinary neurotransmitter testing levels in treatment of depression, ADHD, etc. are low, the system inappropriately excretes the serotonin and dopamine neurotransmitters. This is the phase 1 response. If you increase the 5-HTP, tyrosine, levodopa, and cysteine dosing when the serotonin and dopamine urinary neurotransmitter testing levels in treatment of depression, ADHD, etc. are adequate, the system appropriately excretes the urinary serotonin and dopamine neurotransmitters. This is the phase 3 response. If serotonin and dopamine urinary neurotransmitter testing levels in treatment of depression, ADHD, etc. are below the therapeutic range (very low) and being excreted at an appropriate rate, they are in the phase 2 response. The therapeutic range of dopamine is 475 to 775 micrograms of dopamine per gram of creatinine. The therapeutic range of serotonin is 800 to 2,400 micrograms of serotonin per gram of creatinine. Obtaining serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. in the neurotransmitter therapeutic range is not sufficient for optimal relief of symptoms. You need to determine the phase of the urinary serotonin an d dopamine neurotransmitter levels in order to provide meaning and guidance to the report. |
| 
| 
|
| | Debunking the urban legends of | | URINARY neurotransmitter testing | | The following statements are true |
|
| Urinary serotonin and dopamine molecules found on serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. are not serotonin and dopamine filtered by the kidneys then excreted into the urine, they are serotonin and dopamine molecules that are synthesized by the kidneys from dopa and 5-HTP. then excreted into the urine or secreted into the system. Urinary serotonin and dopamine neurotransmitters are not neurotransmitters that have been in the central or peripheral nervous systems. |
| | | The neurotransmitter molecules of serotonin, dopamine, norepinephrine, epinephrine do not cross the blood brain barrier. If they did starting a dopamine drip on a Parkinson patient would give profound relief of Parkinson symptoms, which it does not. |
| | | Serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. has no value in making a diagnosis of diseases associated with low neurotransmitter levels. |
| | | Serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. prior to starting amino acids has no value if the goal of treatment is relief of symptoms. |
| | | Serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. has no value in treating disease symptoms if the goal is to establish therapeutic or optimal urinary neurotransmitter levels without determining the neurotransmitter phase response. |
| | | Serotonin and dopamine urinary neurotransmitter testing in treatment of depression, ADHD, etc. is only of value in treating symptoms when the goal of treatment is to establish urinary serotonin and dopamine levels in "The Phase 3 Therapeutic Response" during co-administration of serotonin and dopamine precursors 5-HTP, tyrosine, levodopa, and cysteine. |
|
|
| | | BACK TO LITERATURE PAGE | | | home pagkeyz keyb
e | | | | |
|
